<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 成人综合婷婷国产精品久久蜜臀| 男人av无码天堂| 亚洲日本欧洲二区精品| 无码av永久免费大全| 国产午夜福利精品片久久| 香蕉乱码成人久久天堂爱| 欧美国产精品啪啪| 黑人巨大AV在线播放无码| 少妇做爰免费视频网站| 日本欧美大码a在线观看| 东京热久久综合久久88| 国产精品小粉嫩在线观看| 全免费A级毛片免费看无码| 夜爽8888视频在线观看| 四虎精品国产永久在线观看| 麻豆av字幕无码中文| 国产一区二区三区av在线无码观看| 国产成人99亚洲综合精品| 不卡一区二区三区在线视频 | 亚洲国产成人麻豆精品| 日韩人妻无码一区二区三区99| 成人影院免费观看在线播放视频| 久久综合免费一区二区三区| 国产黄色一区二区三区四区| 天天爽夜夜爽人人爽曰| 精品国内自产拍在线观看| 欧美精品一产区二产区| 青草青草久热精品视频在线播放 | 欧洲亚洲国内老熟女超碰| 精品2020婷婷激情五月| 正在播放国产剧情亂倫| 夜夜高潮夜夜爽夜夜爱爱| 377P欧洲日本亚洲大胆| 久久精品人人做人人爽97| 公喝错春药让我高潮| 野花香在线视频免费观看大全| 国产精品一区在线免费看| 首页 动漫 亚洲 欧美 日韩| 国产精品一区二区三区黄色| 免费人成在线观看网站| 午夜福利宅福利国产精品|